
What Is MK-677 (Ibutamoren)? Not a Peptide, Same Risks
MK-677 is an unapproved oral ghrelin mimetic, not a peptide. What the trials showed, side effects, the heart failure signal, FDA Category 2 and WADA ban.
Written by Dr. Andrii Kaleniuk. Updated November 20, 2026.
MK-677 (ibutamoren) is an experimental oral drug that raises growth hormone by mimicking the hunger hormone ghrelin; it is not a peptide and not a SARM, and it has never been approved as a medicine. It was developed by Merck in the 1990s as a small molecule that could be swallowed, unlike injectable peptide growth hormone secretagogues (drugs that prompt the body to release its own growth hormone). In a two-year trial in healthy older adults, it raised growth hormone and IGF-1 to young-adult levels and added about a kilogram of lean mass, but it did not improve strength or physical function, and it raised blood sugar, appetite and body weight. A trial in older adults recovering from hip fracture was stopped early because of a safety signal of congestive heart failure. As of November 2026, the FDA keeps ibutamoren on its Category 2 list of compounding substances with significant safety risks, and the World Anti-Doping Agency (WADA) bans it at all times. This guide explains what MK-677 is, what the trials showed, its side effects and its legal status.
MK-677 (Ibutamoren): The Short Answer
- 1What it is: an oral small-molecule ghrelin mimetic that raises growth hormone and IGF-1; not a peptide, not a SARM.
- 2Approval: never approved as a medicine; experimental in the US and Australia.
- 3Muscle: about 1.1 kg more lean mass than placebo over two years in older adults, with no gain in strength or function.
- 4Side effects: more appetite, weight gain, higher blood sugar, lower insulin sensitivity, higher cortisol, leg swelling and muscle pain.
- 5Heart: a hip fracture trial was stopped early for a congestive heart failure signal.
- 6Rules: FDA Category 2 for compounding; banned by WADA under S2.2.4.
What Is MK-677 (Ibutamoren)?
MK-677, also called MK-0677, L-163,191 or ibutamoren mesylate, was described by Merck researchers in 1995 as a "potent, orally active growth hormone secretagogue." In early dog studies, oral doses raised growth hormone with minimal effect on other pituitary hormones, apart from a modest rise in cortisol. It was later tested in people for muscle wasting, frailty, recovery after hip fracture and Alzheimer's disease. None of those programmes led to an approved product. Australia's Healthy Male describes it as experimental with no approved uses.
Is MK-677 a Peptide or a SARM?
Neither. Peptides are short chains of amino acids, usually injected because the gut digests them. A 2018 review in Sexual Medicine Reviews describes ibutamoren as an orally available small-molecule drug, in contrast to peptide growth hormone secretagogues. Ipamorelin, sermorelin and CJC-1295 are examples of injectable peptides that also raise growth hormone. SARMs (selective androgen receptor modulators) act on testosterone receptors, which MK-677 does not. It is lumped in with peptides because it does a similar job to peptide secretagogues and is sold by the same online "research chemical" shops. For comparison with an actual peptide that works through the same receptor, see what ipamorelin is.
How Does MK-677 Raise Growth Hormone?
MK-677 activates the ghrelin receptor, also called the growth hormone secretagogue receptor. Ghrelin is a gut hormone that signals hunger and also prompts the pituitary gland to release growth hormone. Growth hormone then raises IGF-1, a growth factor made mainly in the liver. Because MK-677 mimics ghrelin, it also tends to increase appetite, and in trials it nudged up cortisol, a stress hormone. That hunger and cortisol effect is shared with some peptide secretagogues; ipamorelin's profile is compared in does ipamorelin raise cortisol or prolactin.
What Did the Human Trials Actually Show?
Only a handful of controlled human trials have been published, and they were done in older or ill people, not in healthy young adults who lift weights. Where a dose is mentioned below, it is the dose tested in that trial, not a recommendation.
Key human trials of MK-677
Murphy et al., 1998 (J Clin Endocrinol Metab)
Study design and numbers not verified by us
Its title reports that MK-677 reversed diet-induced catabolism (protein breakdown); we did not read the abstract
Nass et al., 2008 (Ann Intern Med)
65 healthy adults aged 60-81; 25 mg daily or placebo for 2 years
GH and IGF-1 to young-adult levels; lean mass +1.1 kg vs -0.5 kg; no gain in strength or function; glucose and insulin resistance rose
Sevigny et al., 2008 (Neurology)
Mild to moderate Alzheimer's disease; 1 year; 416 participants according to ScienceDaily
IGF-1 rose but disease progression was not slowed
Adunsky et al., 2011 (Arch Gerontol Geriatr)
123 older adults after hip fracture; 25 mg/day (62) or placebo (61)
No significant gain in stair-climbing power; gait speed improved; stopped early for a heart failure signal
Does MK-677 Build Muscle or Strength?
It adds some lean mass but has not been shown to make people stronger. In the 2008 trial by Nass and colleagues, fat-free mass rose by 1.1 kg on MK-677 and fell by 0.5 kg on placebo over two years. But total body weight rose by 2.7 kg against 0.8 kg, limb fat rose by 1.1 kg against 0.24 kg, and visceral (belly) fat did not change. Strength and physical function did not improve. Fat-free mass includes water, and MK-677 can cause fluid retention, so part of the gain may be water rather than muscle. In the hip fracture trial, the main outcome, stair-climbing power, did not improve significantly (p=0.292), although gait speed did (p=0.011) and IGF-1 rose by 51.4 ng/mL. A 2018 review noted that few long-term controlled studies exist.
What Are the Side Effects of MK-677?
The side effects seen in trials follow from what the drug does: more ghrelin activity means more hunger, and more growth hormone means fluid retention and reduced insulin sensitivity.
MK-677 side effects reported in trials
Increased appetite
Appetite rose, then subsided within months
Nass 2008
Weight gain
+2.7 kg vs +0.8 kg on placebo over 2 years
Nass 2008
Higher blood sugar
Fasting glucose +0.3 mmol/L (5 mg/dL); insulin sensitivity fell
Nass 2008
Higher cortisol
+47 nmol/L (1.7 µg/dL)
Nass 2008
Leg swelling (edema)
Transient, mild lower-leg swelling
Nass 2008
Muscle pain
Reported
Nass 2008
Congestive heart failure
Safety signal in a limited number of patients; trial stopped early
Adunsky 2011
LDL cholesterol
-5.4 mg/dL
Nass 2008
A small rise in fasting glucose may look minor, but it was seen in healthy volunteers under trial monitoring; people with prediabetes or diabetes could be affected more, and the review authors flagged raised glucose as a concern. Similar fluid and glucose issues come up with other growth hormone boosters, as covered in ipamorelin side effects, CJC-1295 and ipamorelin side effects, tesamorelin side effects and sermorelin side effects.
Why Was an MK-677 Trial Stopped for Heart Failure?
In the phase IIb trial published by Adunsky and colleagues in 2011, 123 older adults recovering from hip fracture received MK-0677 or placebo. The authors wrote that the "trial was terminated early due to a safety signal of congestive heart failure in a limited number of patients" and concluded that the drug had an unfavourable safety profile in this population. We could not confirm exactly how many cases there were. Congestive heart failure means the heart cannot pump well enough to keep up with the body's needs, often with fluid build-up. Fluid retention is a known effect of raising growth hormone, which may be relevant, but the trial did not prove a mechanism. The FDA cites this trial as the reason ibutamoren poses significant safety risks.
Is MK-677 FDA-Approved or Legal to Compound?
MK-677 has never been FDA-approved as a medicine, and the FDA's safety listing means pharmacies should not compound it. The FDA placed ibutamoren mesylate in Category 2, its list of bulk substances that may present significant safety risks, for outsourcing facilities (503B) on December 29, 2022 and for traditional compounding pharmacies (503A) on September 29, 2023. The FDA says it "poses significant safety risks due to the potential for congestive heart failure in certain patients," citing the hip fracture trial. In April 2026 the FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2, according to a compounding trade newsletter; ibutamoren was not among them, and the FDA page updated April 22, 2026 still lists it. The wider rule changes are explained in FDA peptide rules in 2026.
Is MK-677 Banned in Sport?
Yes. The WADA 2026 Prohibited List, in force since January 1, 2026, names ibutamoren (MK-677) under section S2.2.4, growth hormone secretagogues and their mimetics, alongside anamorelin and capromorelin. It is prohibited at all times, in and out of competition, and is classed as a non-Specified substance. Athletes in drug-tested sport should avoid it entirely. Other banned growth hormone boosters are listed in peptides banned by WADA.
What About "Research Use Only" MK-677?
Most MK-677 sold online is labelled "for research use only" or "not for human consumption." That label does not make it legal or safe to take. These products are not made under drug manufacturing standards, nobody checks that the capsule or liquid contains what the label says, and there is no prescriber to monitor blood sugar or swelling. Why this labelling exists and why it offers no protection is explained in research use only peptides.
Who Should Be Especially Careful?
- 1People with heart disease or heart failure, or older adults recovering from surgery or fractures, given the trial signal.
- 2People with prediabetes, diabetes or insulin resistance, because MK-677 raised glucose and lowered insulin sensitivity.
- 3Anyone in drug-tested sport.
- 4People who are pregnant or breastfeeding, for whom there are no data.
When to Talk to Your Doctor
- 1You have taken or are taking MK-677 and notice swelling of the legs, breathlessness or rapid weight gain.
- 2You feel unusually thirsty, urinate more often or have blurred vision, which can signal high blood sugar.
- 3You have heart, kidney or liver disease, or diabetes, and are considering any growth hormone booster.
- 4You want help with muscle loss, frailty or low energy and want to know which approved treatments exist.
- 5You have chest pain or severe shortness of breath (call emergency services).
What to Do Next: Questions to Ask Your Doctor
- 1Should I have my fasting glucose, HbA1c and IGF-1 checked if I have used MK-677?
- 2Could my symptoms (swelling, fatigue, hunger) be related to it?
- 3Is there an approved treatment for my goal, such as muscle loss, recovery or body composition?
- 4Would strength training and protein intake give me similar benefits with fewer risks?
- 5If I compete, how long could MK-677 affect a drug test, and who should I contact?
The Bottom Line
MK-677 is an oral small molecule, not a peptide, that raises growth hormone and IGF-1 by mimicking ghrelin. In the trials, it added about a kilogram of lean mass in older adults without improving strength or function, raised appetite, weight, blood sugar and cortisol, and was linked to a heart failure signal that stopped a hip fracture trial. It has never been approved, the FDA lists it as a significant safety risk for compounding, and WADA bans it at all times. The evidence does not support using it.
FAQ
No. MK-677 (ibutamoren) is an orally available small-molecule drug that mimics ghrelin. It is often sold alongside peptides because it also raises growth hormone.
No. SARMs act on androgen (testosterone) receptors. MK-677 acts on the ghrelin receptor to release growth hormone.
A trial in older adults after hip fracture was stopped early for a safety signal of congestive heart failure. The FDA cites this as a significant safety risk.
Yes. In a two-year trial, fasting glucose rose by about 5 mg/dL and insulin sensitivity fell compared with placebo.
It is not FDA-approved, and it is on the FDA's Category 2 list, which means pharmacies should not compound it. Products sold as research chemicals are unregulated.
Yes. It is named under S2.2.4 of the WADA 2026 Prohibited List and is banned at all times.
Sources
- 1Nass R, et al. Two-year randomized trial of MK-677 in older adults, Annals of Internal Medicine, 2008
- 2Adunsky A, et al. Phase IIb trial of MK-0677 after hip fracture, Archives of Gerontology and Geriatrics, 2011
- 3Murphy MG, et al. MK-677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism, Journal of Clinical Endocrinology and Metabolism, 1998
- 4Merck researchers. Discovery report of L-163,191 (MK-0677), Proceedings of the National Academy of Sciences, 1995
- 5Sigalos JT, Pastuszak AW. Review of growth hormone secretagogues including ibutamoren, Sexual Medicine Reviews, 2018
- 6US Food and Drug Administration. Bulk drug substances that may present significant safety risks (Category 2), FDA, updated April 22, 2026
- 7World Anti-Doping Agency. 2026 Prohibited List (copy), WADA, 2026
- 8German Sport University Cologne. Summary of WADA class S2, German Sport University Cologne
- 9ScienceDaily. Report on the Alzheimer's disease trial of MK-677 (Sevigny JJ, et al., Neurology 2008), ScienceDaily, November 17, 2008
- 10503Pharma newsletter. Report on FDA removal of 12 peptides from Category 2, 503Pharma, April 15, 2026
- 11Healthy Male. Consumer article on MK-677 (ibutamoren), Healthy Male (Australia)
This article summarizes published research and regulatory documents for general information and does not replace advice from your doctor. MK-677 was originally developed by Merck.

Dr. Andrii Kaleniuk
Author
Comments (0)
Be the first to comment on this article.




